Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis

Venkatesh L. Murthy, MD, PhD; Bing Yu, PhD; Wenshuang Wang, PhD; Xiuyan Zhang, MPH; Taryn Alkis, MS; Alexander R. Pico, PhD; Ashish Yeri, PhD; Shilpa N. Bhatnariju, PhD; Jan Bressler, PhD; Christie M. Ballantyne, MD; Jane E. Freedman, MD; Jose Ordovas, PhD; Eric Boerwinkle, PhD; Katherine L. Tucker, PhD; Ravi Shah, MD

IMPORTANCE Cardiometabolic disease is responsible for decreased longevity and poorer cardiovascular outcomes in the modern era. Metabolite profiling provides a specific measure of global metabolic function to examine specific metabolic mechanisms and pathways of cardiometabolic disease beyond its clinical definitions.

OBJECTIVES To define a molecular basis for cardiometabolic stress and assess its association with cardiovascular prognosis.

DESIGN, SETTING, AND PARTICIPANTS A prospective observational cohort study was conducted in a population-based setting across 2 geographically distinct centers (Boston Puerto Rican Health Study [BPRHS], an ongoing study of individuals enrolled between June 1, 2004, and October 31, 2009; and Atherosclerosis Risk in Communities [ARIC] study, whose participants were originally sampled between November 24, 1986, and February 10, 1990, and followed up through December 31, 2017). Participants in the BPRHS were 668 Puerto Rican individuals with metabolite profiling living in Massachusetts, and participants in the ARIC study were 2152 individuals with metabolite profiling and long-term follow-up for mortality and cardiovascular outcomes. Statistical analysis was performed from October 1, 2018, to March 13, 2020.

EXPOSURE The primary exposure was metabolite profiles across both cohorts.

MAIN OUTCOMES AND MEASURES Outcomes included associations with multisystem cardiometabolic stress and all-cause mortality and incident coronary heart disease (in the ARIC study).

RESULTS Participants in the BPRHS (N = 668; 491 women; mean [SD] age, 57.0 [7.4] years; mean [SD] body mass index [calculated as weight in kilograms divided by height in meters squared], 32.0 [6.5]) had higher prevalent cardiometabolic risk relative to those in the ARIC study (N = 2152; 599 African American individuals; 1213 women; mean [SD] age, 54.3 [5.7] years; mean [SD] body mass index, 28.0 [5.5]). Multisystem cardiometabolic stress was defined for 668 Puerto Rican individuals in the BPRHS as a multidimensional composite of hypothalamic-adrenal axis activity, sympathetic activation, blood pressure, proatherogenic dyslipidemia, insulin resistance, visceral adiposity, and inflammation. A total of 260 metabolites associated with cardiometabolic stress were identified in the BPRHS, involving known and novel pathways of cardiometabolic disease (eg, amino acid metabolism, oxidative stress, and inflammation). A parsimonious metabolite-based score associated with cardiometabolic stress in the BPRHS was subsequently created; this score was applied to shared metabolites in the ARIC study, demonstrating significant associations with coronary heart disease and all-cause mortality after multivariable adjustment at a 30-year horizon (per SD increase in metabolomic score: hazard ratio, 1.14; 95% CI, 1.00-1.31; P = .045 for coronary heart disease; and hazard ratio, 1.15; 95% CI, 1.07-1.24; P < .001 for all-cause mortality).

CONCLUSIONS AND RELEVANCE Metabolites associated with cardiometabolic stress identified known and novel pathways of cardiometabolic disease in high-risk, community-based cohorts and were associated with coronary heart disease and survival at a 30-year time horizon. These results underscore the shared molecular pathophysiology of metabolic dysfunction, cardiovascular disease, and longevity and suggest pathways for modification to improve prognosis across all linked conditions.

JAMA Cardiol. doi:10.1001/jamacardio.2020.2686
Published online July 22, 2020.

© 2020 American Medical Association. All rights reserved.
Despite ongoing efforts in the prevention of cardiovascular disease, recent reports suggest a relative plateau in mortality owing to major cardiometabolic diseases (CMD) and cardiovascular diseases (CVD).\(^1\) Cardiovascular disease is recognized as a shared risk factor for both cardiovascular and noncardiovascular morbidity, predating neurocognitive, renal, Cardiovascular and functional decline. These observations have been distilled into clinical prevention guidelines and definitions (eg, metabolic syndrome). Nevertheless, for therapeutic discovery, these constructs are based on clinical phenotypes (eg, blood pressure and lipid levels), lacking resolution for the molecular components of metabolic homeostasis that may pinpoint specific, mutable pathways relevant to CVD. This limitation becomes especially important at the extremes of clinical risk, where earlier detection and more specific metabolic biomarkers may be relevant to defining the hazard of CMD in association with CVD over a longer time horizon.

Our primary hypothesis was that circulating metabolites associated with a composite marker of cardiometabolic (CM) stress would identify underlying pathways relevant to CVD and survival and would be associated with these outcomes across 2 racially diverse cohorts at high prevalent CMD risk. We first studied 668 Puerto Rican adults in the Boston Puerto Rican Health Study (BPRHS) with metabolite profiling to identify molecular correlates and pathways of a validated, multiparametric clinical index of CM stress based on known and emerging CMD traits. We derived a metabolite-based score from this clinical index and subsequently applied the metabolite-based score to a separate cohort of 2152 participants in the Atherosclerosis Risk in Communities (ARIC) study to investigate its association with the development of long-term coronary heart disease (CHD) and all-cause mortality over 30 years independent of sex, race/ethnicity, and other purposed as part of a case-control study for diabetes (120 cases and 120 controls without diabetes), and the remainder were randomly selected. After exclusion for missing clinical covariates (age, sex, body mass index [BMI], smoking status, and CM stress index) and metabolites with high missingness (>25%), 668 participants with 719 metabolites comprised our final analytic cohort.

**Cohort Description**

**Boston Puerto Rican Health Study**
The BPRHS is an ongoing longitudinal study of 1499 individuals enrolled between June 1, 2004, and October 31, 2009, that sought to examine stress, nutrition, and CVD outcomes in Puerto Rican immigrants in the Boston area. The design of the overall study has been previously published.\(^2\) In brief, eligible participants were of self-identified Puerto Rican descent, able to answer questions in English or Spanish, 45 to 75 years of age, and living in the Boston, Massachusetts, area at study enrollment. Detailed survey methods have been reported\(^2\) (eAppendix in the Supplement). Blood samples were collected for biochemical measures after a 12-hour fast (dehydroepiandrosterone sulfate, hemoglobin A\(_1c\), C-reactive protein, a lipid panel, and glucose), and a 12-hour urine collection was performed for urinary epinephrine and norepinephrine levels. The BPRHS cohort study procedures were approved by the Tufts Medical Center Institutional Review Board. The current BPRHS data analysis was approved by the University of Massachusetts Lowell and Massachusetts General Hospital Institutional Review Boards.

Our construction of an analytic cohort is shown in eFigure 1 in the Supplement. Of the 1499 individuals in the baseline study visit, 817 individuals had metabolite profiling performed. The metabolite profiling was performed on archived plasma at 2 different times (“technical runs”; run 1, n = 736; run 2, n = 81). We focused on the 736 study participants, with their samples performed on the same platform to reduce technical variability. Among these, a subset of the 736 samples for metabolite profiling in the BPRHS was selected for other purposes as part of a case-control study for diabetes (120 cases and 120 controls without diabetes), and the remainder were randomly selected. After exclusion for missing clinical covariates (age, sex, body mass index [BMI], smoking status, and CM stress index) and metabolites with high missingness (>25%), 668 participants with 719 metabolites comprised our final analytic cohort.

**Methods**

**ARIC Study**
The ARIC study is a prospective cohort study of 15,792 individuals, originally sampled between November 24, 1986, and February 10, 1990. The detailed design of the ARIC study has been previously published.\(^3\) The ARIC study participants were 45 to 64 years of age from 4 US communities (Forsyth County, North Carolina; Jackson, Mississippi; suburbs of Minneapolis, Minnesota; and Washington County, Maryland) and underwent collection of standard demographic, clinical, and biochemical measures. Clinical measures included vital signs and anthropometric indices,\(^1\) lipid profiles,\(^4,5\) and glomerular filtration rate\(^2\) (eAppendix in the Supplement). Our analytic cohort consisted of 2152 participants with metabolites measured in 2014 from serum stored at a study visit during the period from 1987 to 1989, as well as CHD and mortality follow-up information and necessary covariates. Our primary out-
comes were CHD and all-cause mortality. In the ARIC study, prevalent CHD at baseline was defined as a self-reported history of physician-diagnosed myocardial infarction, coronary artery bypass surgery, or coronary angioplasty or electrocardiogram evidence of a previous myocardial infarction. Prevalent CVD was defined as evidence of prior CHD, heart failure, or stroke. Incident CHD was defined as definite fatal CHD and definite or probable myocardial infarction that occurred on or before December 31, 2017. The cases were identified and adjudicated using information from study visits, interviews, annual follow-up calls, hospital discharge lists, medical records, and death certificates. Only 1947 (of 2152) participants without prevalent CHD (and with CHD follow-up and all covariates available for adjustment) at the baseline examination were included in incident CHD models. The vital status for each individual was followed from the baseline visit until death, loss to follow-up, or administrative censoring at December 31, 2017. Of the overall 2152 individuals, 2076 were included in mortality models with all covariates available for adjustment.

**Metabolite Profiling**

Metabolite profiling was performed at a commercial facility (Metabolon Inc) using proprietary procedures. For the BPRHS, the Metabolon metabolomics platform uses liquid chromatography-mass spectrometry methods with positive ion and negative ion modes (eAppendix in the Supplement). Metabolites sampled across 4 modes were detected: (1) acidic positive ion (optimized for hydrophilic molecules), (2) acidic positive ion (optimized for hydrophobic molecules), (3) basic negative ion, and (4) negative ionization from eluent of a HILIC (hydrophilic interaction liquid chromatography) column. Raw data were extracted and peaks identified using proprietary methods, with more than 3300 commercially available purified molecules as reference. Metabolites without specific chemical annotation were also detected. The relative metabolite concentration was reported as a normalized area under the curve value for each metabolite. Missing values were imputed as 50% of the minimal value across all participants, and metabolites were subsequently log2-transformed and standardized (to mean, 0; variance, 1) for entry into analysis. Methods for the BPRHS (from Metabolon) are reported in the eAppendix in the Supplement.

For the ARIC study validation cohort (performed earlier than the BPRHS metabolomics), gas chromatography was used in addition to liquid chromatography for several platforms. The details of metabolite profiling in the ARIC study have been published elsewhere for reference. The median relative SD for internal standards was 2% for the ARIC study and 5% for the BPRHS, with total process variability of 10% or less. Recent consortium reports for Metabolon’s platform in other samples have reported a median coefficient of variation of 14.6% across replicates for known metabolites, with a median coefficient of variation of 29% from day to day.

**Definition of CM Stress in the BPRHS**

The index of CM stress used here has been previously validated in the BPRHS as a marker of multisystem metabolic stress associated with disease (Table 1). The stress index comprehensively quantifies metabolic, inflammatory, and neurohormonal states across multiple dimensions: (1) hypothalamus-adrenal axis (serum dehydroepiandrosterone sulfate and

### Table 1. Definition of Cardiometabolic Stress Index and Its 9 Components in the Boston Puerto Rican Health Study

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure and antihypertensive medication use</td>
<td>0 SBP ≤140 mm Hg, DBP ≤90 mm Hg, and no antihypertensive medication use reported</td>
</tr>
<tr>
<td>1 All others</td>
<td></td>
</tr>
<tr>
<td>2 SBP &gt;140 mm Hg and DBP &gt;90 mm Hg</td>
<td></td>
</tr>
<tr>
<td>Waist circumference</td>
<td>0 Other</td>
</tr>
<tr>
<td>1 &gt;102 cm for Male patients; &gt;88 cm for female patients</td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia or use of medications for lipids</td>
<td>0 HDL-C ≥40 mg/dL, total cholesterol &lt;240 mg/dL, and no antilipidemic medications reported</td>
</tr>
<tr>
<td>1 All others</td>
<td></td>
</tr>
<tr>
<td>2 HDL-C &lt;40 mg/dL and total cholesterol ≥240 mg/dL (regardless of medication) or HDL-C &lt;40 mg/dL and total cholesterol ≥240 mg/dL with medication use</td>
<td></td>
</tr>
<tr>
<td>HbA1c and antidiabetes medication use</td>
<td>0 HbA1c ≤7% and no antidiabetes medication use reported</td>
</tr>
<tr>
<td>1 HbA1c &gt;7% or antidiabetes medication use reported</td>
<td></td>
</tr>
<tr>
<td>Urinary cortisol</td>
<td>0 &lt;41.5 μg/g Creatinine for male patients or &lt;49.5 μg/g creatinine for female patients</td>
</tr>
<tr>
<td>1 All others</td>
<td></td>
</tr>
<tr>
<td>Urinary epinephrine</td>
<td>0 &lt;2.8 μg/g Creatinine for male patients or &lt;3.6 μg/g creatinine for female patients</td>
</tr>
<tr>
<td>1 All others</td>
<td></td>
</tr>
<tr>
<td>Urinary norepinephrine</td>
<td>0 &lt;30.5 μg/g Creatinine for male patients or &lt;46.9 μg/g creatinine for female patients</td>
</tr>
<tr>
<td>1 All others</td>
<td></td>
</tr>
<tr>
<td>Serum DHEA-S</td>
<td>0 All others</td>
</tr>
<tr>
<td>1 ≤589.5 ng/mL or Taking androgens for male patients or ≤368.5 ng/mL or taking androgens for female patients</td>
<td></td>
</tr>
<tr>
<td>C-reactive protein</td>
<td>0 All others</td>
</tr>
<tr>
<td>1 &gt;3 mg/L</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DHEA-S, dehydroepiandrosterone sulfate; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; SBP, systolic blood pressure.
urinary cortisol levels), (2) sympathetic activation (12-hour urinary norepinephrine and epinephrine levels), (3) vascular dysfunction (blood pressure), (4) proatherogenic dyslipidemia, (5) insulin resistance or type 2 diabetes, (6) visceral adiposity, and (7) inflammation (C-reactive protein levels). Use of medications for type 2 diabetes, hypertension, or dyslipidemia was incorporated into this index. Each component was parameterized into a 0-point to 1-point scale or a 0-point to 20-point scale and summed to generate the final systemic CM stress index. The operating characteristics for biochemical assays used in the prescription of this index (urinary and plasma or serum biomarkers) have been previously reported, and the study-specific cutoffs for these biochemical measures have been prescribed by previous work in the BPRHS.

### Statistical Analysis

#### Identification of Metabolites Associated With the CM Stress Index

Statistical analysis was performed from October 1, 2018, to March 13, 2020. After filtering and imputation, metabolites were subsequently log-transformed and then mean-centered and standardized (to mean, 0; variance, 1). We measured the association of the CM stress index as a function of each metabolite, adjusted for age, sex, BMI, and ever smoking status in separate linear models. We adjusted for multiple hypothesis testing across all models using the Benjamini-Hochberg false discovery rate threshold of 5%, finding 260 metabolites significantly associated (false discovery rate threshold <0.05) with the CM stress index (BPRHS; eFigure 1 in the Supplement).

#### Pathway Analysis

To provide an analysis of molecular pathways relevant to CVD based on CM stress, we identified genes whose protein products were along the enzymatic pathways of top CM stress-associated metabolites and performed a comprehensive pathway analysis on these genes. Of the 260 metabolites, 124 were annotated with KEGG Compound identification (ID) numbers using MetaboAnalyst. Using these ID numbers as a query set, we next constructed a network of metabolic pathways consisting of 375 metabolites, 300 reaction nodes, 210 enzyme classes, 427 genes, and 1563 interactions using the MetScape app in Cytoscape. Using the RCy3 package for R-Cytoscape scripting, we interrogated the network to identify sets of genes linked to metabolites associated with CM stress. We assigned minimum, mean, and maximum β coefficient values to each pathway gene based on its connectivity to analyzed metabolites via the enzyme–metabolite interactions curated by MetScape. These values were used to define metabolically harmful and metabolically healthy gene sets (eg, genes having a positive-maximum and negative-minimum metabolite-associated β coefficient value, respectively). These genes were used to perform a pathway analysis using WikiPathways via the clusterProfiler R package. In addition to the typical caveats for pathway analysis as a strictly exploratory method, the mapping from metabolites to genes via incomplete and continually updated databases may introduce bias.

### Construction of Metabolite-Based Score Reflecting CM Stress (BPRHS)
From 260 metabolites associated with the CM stress index in the BPRHS, 125 metabolites were commonly expressed with the ARIC study (matched by Metabolon chemical ID number, Human Metabolome Database ID, mass, and/or name) and expressed in more than 75% of the ARIC study participants. We used elastic net regression in the BPRHS to create a metabolite-based CM stress score based on the clinical CM stress index as a function of age, sex, and the 125 common metabolites. Selection of α and λ parameters was optimized by 10-fold cross-validation (with 5 repeats), and age and sex were not penalized in regressions (using caret in R (R Foundation for Statistical Computing)). Data from the BPRHS were used to construct the score, with the knowledge that external validation against outcomes in the ARIC study would mitigate overfitting of the metabolite-based score in the BPRHS. To achieve maximal parsimony in constructing the score, we ranked all 125 metabolites by calculating the variable importance in the elastic net and specified successive linear models for the clinical CM stress index in the BPRHS as a function of age, sex, and increasing number of metabolites (with initial models including the most important metabolites). The predictive ability of linear models was assessed in 10-fold cross-validation (5 repeats). We plotted the cross-validated model $R^2$ and variable importance as a function of sets of metabolites to determine the minimal number of metabolites necessary to optimize model fit. We report the 30 metabolite model in the ARIC study for parsimony.

### Survival Analysis for 30-Year CHD and Mortality (ARIC Study)

For the ARIC study, imputation of below-detection values was done as in the BPRHS, and metabolites were log-transformed, mean-centered, and standardized for analysis. Cox proportional hazards regression models were constructed for CHD and all-cause mortality as a function of metabolite-based CM stress score. Survival analysis included 2 models: model 1 comprised age, sex, and race/ethnicity adjusted for center, and model 2 comprised all the factors in model 1, with added adjustment for traditional risk factors (smoking status, systolic blood pressure, use of medications for hypertension, diabetes status, total cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate for incident CHD analysis). All-cause mortality analysis was further adjusted for BMI and prevalent CVD. For CHD, we performed a sensitivity analysis, including the Pooled Cohort Equations risk as defined and examining the association of CM stress score and CHD adjusted for center, sex, and pooled Cohort Equations score. The Cox proportional hazards regression assumption was assessed by visual inspection of residual plots and by inclusion of time by metabolomic score linear interaction terms (with interaction $P > .05$ indicating no violation of proportionality). Effect modification by sex was assessed. We calculated the mean value and 95% CI of the area under the curve with 10-fold cross-validation with 100 replicates. The net reclassification index and integrated discrimination improvement were calculated as described. All statistical analyses were performed using R, version 3.5.2 or
SAS, version 9.4 (SAS Institute Inc). A 2-tailed \( P < .05 \) was considered statistically significant, with adjustments for type I error as specified.

## Results

### Cohort Characterization

Characteristics of the BPRHS and ARIC study subsamples included in this analysis are shown in Table 2. The BPRHS subsample (n = 668) had a mean (SD) age of 57.0 (7.4) years and included 491 women (73.5%). The mean (SD) BMI was 32.0 (6.5) calculated as weight in kilograms divided by height in meters squared, and most of the cohort was at high prevalent CM risk: 345 participants (51.6%) had a diagnosis of diabetes, 469 (70.2%) had a diagnosis of hypertension, and 432 (64.7%) had a diagnosis of dyslipidemia. The 2152 ARIC study participants (599 African American individuals and 1553 European American individuals) had a similar age distribution to the BPRHS and were matched between the ARIC study and the BPRHS, with a 10-fold cross-validation approach (5 repeats) for specifica- tion of the \( \alpha \) and \( \lambda \) parameters (eTable 2 in the Supplement, a 10-fold cross-validation approach (5 repeats) for specifica-

### Molecular Pathways of CM Stress

After adjustment for age, sex, BMI, and smoking status, we found 260 metabolites significantly associated with CM stress (eTable 1 in the Supplement). The identified metabolites fit broadly into 3 major categories: (1) those with a previously reported association with CVD, diabetes, or longevity (eg, glutamate, taurine, isoleucine, valine, 2-aminoadipate, and aconi- tate); (2) those associated with diseases specified in the CM stress definition (eg, glucose, cholesterol, androgens, and cat-

cidaline intermediates); and (3) several novel biomolecules (mainly lipids) not commonly described as functional biomarkers of inflammation or CVD. We next used experimentally defined metabolite-enzyme interactions from MetScape14 to identify enriched pathways of CM stress from WikiPathways (Figure 1). Pathways shared across both metabolically harmful and metabolically healthy gene sets included amino acid metabolism, Ras signaling, eicosanoid synthesis, and the Nrf2 pathway.

### Construction of Metabolite-Based CM Stress Score

We trained an elastic net model (as specified in the Methods) for the CM stress index as a function of 125 metabolites that were matched between the ARIC study and the BPRHS, with a 10-fold cross-validation approach (5 repeats) for specifica-

### Abbreviations

ARIC, Atherosclerosis Risk in Communities; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BPRHS, Boston Puerto Rican Health Study; CM, cardiometabolic; NA, not applicable.

# Table 2. Characteristics of the BPRHS and ARIC Study Subsamples Included in This Analysis

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>BPRHS (n = 668)</th>
<th>ARIC study (n = 2152)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>668 57.0 (7.4)</td>
<td>2152 54.3 (5.7)</td>
</tr>
<tr>
<td>Female sex, No. (%)</td>
<td>668 491 (73.5)</td>
<td>2152 1213 (56.4)</td>
</tr>
<tr>
<td>African American race/ethnicity, No. (%)</td>
<td>NA NA</td>
<td>2152 599 (27.8)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>668 32.0 (6.5)</td>
<td>2149 28.0 (5.5)</td>
</tr>
<tr>
<td>Waist circumference, mean (SD), cm</td>
<td>668 102 (15)</td>
<td>2148 98 (14)</td>
</tr>
<tr>
<td>Type 2 diabetes, No. (%)</td>
<td>668 345 (51.6)</td>
<td>2147 254 (11.8)</td>
</tr>
<tr>
<td>Hypertension, No. (%)</td>
<td>668 469 (70.2)</td>
<td>2142 805 (37.6)</td>
</tr>
<tr>
<td>Dyslipidemia, No. (%)</td>
<td>668 432 (64.7)</td>
<td>2134 1010 (47.3)</td>
</tr>
<tr>
<td>Prevalent cardiovascular disease, No. (%)</td>
<td>668 139 (20.8)</td>
<td>2094 269 (12.8)</td>
</tr>
<tr>
<td>Current smoker, No. (%)</td>
<td>668 151 (22.6)</td>
<td>2152 585 (27.2)</td>
</tr>
<tr>
<td>Blood pressure, mean (SD), mm Hg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>668 136 (19)</td>
<td>2152 122 (20)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>668 81.5 (10.8)</td>
<td>2152 73.6 (11.7)</td>
</tr>
<tr>
<td>Lipid panel, mean (SD), mg/dL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>668 166 (129)</td>
<td>2146 136 (110)</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol</td>
<td>668 45 (13)</td>
<td>2146 52 (17)</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>668 185 (42)</td>
<td>2145 215 (42)</td>
</tr>
<tr>
<td>Glucose, mean (SD), mg/dL</td>
<td>668 119 (50)</td>
<td>2152 110 (42)</td>
</tr>
<tr>
<td>Hemoglobin A1c, mean (SD), %</td>
<td>667 7.0 (1.8)</td>
<td>NA NA</td>
</tr>
<tr>
<td>CM stress index, mean (SD)</td>
<td>668 4.5 (1.9)</td>
<td>NA NA</td>
</tr>
</tbody>
</table>

### Footnotes

Abbreviations: ARIC, Atherosclerosis Risk in Communities; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BPRHS, Boston Puerto Rican Health Study; CM, cardiometabolic; NA, not applicable.

\* Hypertension and dyslipidemia were defined as prescribed by cutoffs used to generate the cardiometabolic stress index. Prevalent cardiovascular disease was self-reported in the BPRHS and was defined as prior evidence of coronary heart disease, heart failure, and stroke in ARIC. Type 2 diabetes is defined in the text.
Association of Metabolite-Based CM Stress With Risk for CHD and Mortality Over 30 Years

Over 30 years of follow-up, we identified 364 cases of incident CHD (16.9%) and 1113 deaths (51.7%) in the ARIC study; a final analytic data set with full covariate availability for survival analysis included 1068 deaths (724 noncardiovascular) and 282 incident CHD events (233 myocardial infarctions and 49 fatal CHD events). The results of survival analysis are shown in Table 3 and Figure 2. We observed an adjusted 14% increased hazard of CHD and 15% increased hazard of all-cause mortality per SD of metabolomic CM stress (CHD: hazard ratio, 1.14 [95% CI, 1.00-1.31]; all-cause mortality: hazard ratio, 1.15 [95% CI, 1.07-1.24]). Although we did not observe an effect modification of the association of CM stress with CHD by sex, we did observe an effect modification of the association of CM stress with mortality; increased metabolomic CM stress was primarily associated with all-cause mortality in women (per SD of metabolomic CM stress for women: hazard ratio, 1.26 [95% CI, 1.14-1.40]; per SD of metabolomic CM stress for men: hazard ratio, 1.06 [95% CI, 0.96-1.18]; P = .01 for interaction), perhaps reflecting the female predominance of the derivation cohort. In a sensitivity analysis including the Pooled Cohort Equation score, we observed similar results (Table 3, model 3). There were no improvements in reclassification or discrimination via addition of metabolite-based CM stress score to adjustment (Table 3, model 2).

Discussion

Our central aim was to understand the molecular basis for CM stress and its association with long-term outcomes relevant to CVD and longevity. In a cohort of Puerto Rican individuals with prevalent CMD, we identified 260 metabolites associated with multisystem CM stress, independent of age, sex, BMI, and smoking. Several metabolites had known association with common pathways of aging, insulin resistance, inflammation, and CVD (eg, glutamate,23 branched-chain amino acids,24-25 2-amino adipate,26 acacetinate,27 ceramides,28 and sphingomyelins29). Mapping these empirical associations onto known enzymatic pathways implicated known and novel genetic-metabolic networks in CMD. We observed significant and modest associations between the metabolite-based CM stress score and CHD and mortality over 30 years in ARIC, independent of CMD traits and CVD risk factors. These findings demonstrate that metabolites linked to CM stress identify important, key metabolic pathway alterations in CMD and are associated with long-term outcomes relevant to CVD for future molecular study.

A slowing in CVD improvement in the face of modern prevention efforts has prompted studies on an associated role for CMD.1 Cardiometabolic disease has classically been defined primarily associated with all-cause mortality in women; increased metabolomic CM stress (CHD: hazard ratio, 1.14 [95% CI, 1.00-1.31]; all-cause mortality: hazard ratio, 1.15 [95% CI, 1.07-1.24]). Although we did not observe an effect modification of the association of CM stress with CHD by sex, we did observe an effect modification of the association of CM stress with mortality; increased metabolomic CM stress was primarily associated with all-cause mortality in women (per SD of metabolomic CM stress for women: hazard ratio, 1.26 [95% CI, 1.14-1.40]; per SD of metabolomic CM stress for men: hazard ratio, 1.06 [95% CI, 0.96-1.18]; P = .01 for interaction), perhaps reflecting the female predominance of the derivation cohort. In a sensitivity analysis including the Pooled Cohort Equation score, we observed similar results (Table 3, model 3). There were no improvements in reclassification or
pro-atherogenic dyslipidemia, visceral adiposity, hypertension, and dysglycemia). Although this construct has been helpful in epidemiology and prevention efforts, its focus on end-phenotypes of CMD limits its ability to resolve specific mechanisms that underlie CMD. In this regard, genetic and epigenetic studies of large human populations have been conducted to understand a potential basis for CMD. In seminal studies of the circulating metabolome in humans, shared metabolic pathways have been associated with components of CMD, including physical activity, insulin resistance, and obesity (eg, fatty acids, branched-chain amino acids, and Krebs cycle). Nevertheless, most of these studies have focused on single components

### Table 3. Multivariable Survival Analysis in the Atherosclerosis Risk in Communities Study

<table>
<thead>
<tr>
<th>Metabolomic risk (HR per SD increase in CM stress)</th>
<th>No. (No. of events)</th>
<th>HR (95% CI)</th>
<th>P value</th>
<th>C (95% CI)b</th>
<th>ΔC (95% CI)b</th>
<th>NRI (95% CI)b</th>
<th>IDI (95% CI)b</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD</td>
<td>Model 1 1947 (282)</td>
<td>1.40 (1.24 to 1.58)</td>
<td>&lt;.001</td>
<td>0.656 (0.621 to 0.691)</td>
<td>0.029 (0.005 to 0.054)</td>
<td>0.142 (0.036 to 0.241)</td>
<td>0.027 (0.011 to 0.048)</td>
</tr>
<tr>
<td></td>
<td>Model 2 1947 (282)</td>
<td>1.14 (1.00 to 1.31)</td>
<td>.045</td>
<td>0.738 (0.704 to 0.772)</td>
<td>0.001 (−0.004 to 0.006)</td>
<td>0.121 (0.024 to 0.230)</td>
<td>0.010 (0.002 to 0.027)</td>
</tr>
<tr>
<td></td>
<td>Model 3 1947 (282)</td>
<td>1.13 (1.00 to 1.28)</td>
<td>.05</td>
<td>0.715 (0.681 to 0.750)</td>
<td>0.002 (−0.004 to 0.008)</td>
<td>−0.007 (−0.124 to 0.104)</td>
<td>0.003 (−0.001 to 0.011)</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>Model 1 2076 (1068)</td>
<td>1.33 (1.24 to 1.41)</td>
<td>&lt;.001</td>
<td>0.685 (0.670 to 0.701)</td>
<td>0.020 (0.011 to 0.028)</td>
<td>0.140 (0.071 to 0.209)</td>
<td>0.028 (0.015 to 0.043)</td>
</tr>
<tr>
<td></td>
<td>Model 2 2076 (1068)</td>
<td>1.15 (1.07 to 1.24)</td>
<td>&lt;.001</td>
<td>0.734 (0.720 to 0.749)</td>
<td>0.003 (0.000 to 0.006)</td>
<td>0.046 (−0.043 to 0.122)</td>
<td>0.005 (0.000 to 0.012)</td>
</tr>
</tbody>
</table>

Abbreviations: CHD, coronary heart disease; CM, cardiometabolic; HR, hazard ratio; IDI, integrated discrimination improvement; NRI, net reclassification index.

* Adjustments: model 1: age, sex, and race/ethnicity adjusted for center; model 2: model 1 plus smoking, systolic blood pressure, use of medications for hypertension, type 2 diabetes status, total cholesterol, high-density lipoprotein cholesterol, and estimated glomerular filtration rate for incident CHD analysis; all-cause mortality analysis was further adjusted for body mass index and prevalent cardiovascular disease; and model 3: for CHD only; adjusted for center, sex, and Pooled Cohort Equation.

* The C statistics and NRI and IDI are computed in reference to models without the CM score added vs those with the CM score added.

* Analyses for incident CHD excluded individuals with prevalent CHD at baseline (accounting for the difference in number of individuals per regression).
of CMD for discovery and do not forge a link between metabolomic signatures of CMD with CVD, a need in therapeutic discovery efforts.

Here, we studied a validated CM stress index to explore the molecular basis for CMD and its association with CVD. The index used in this study incorporates components of a traditional metabolic syndrome as well as systemic inflammation, adrenal, and sympathetic nervous system activity markers of CM stress. Several metabolites uncovered in this study have been previously linked to CMD and CVD, increasing confidence in their reproducibility (eg, glutamate). We also identified several novel molecules associated with CM stress not previously widely reported, to our knowledge (eg, phospholipids, sphingomyelins, and amino acid derivatives). More important, the integrative genetic-metabolic network methods used here suggest that these CM stress–related metabolites may link CMD to central mechanisms of CVD and health. For example, Ras signaling plays a well-established role in CMD, regulating central components of metabolism integral to nutrient processing, insulin resistance, and myocardial hypertrophy (eg, AMPK [5′adenosine monophosphate-activated protein kinase] and mTOR [mammalian target of rapamycin]).30-33 In addition, Nrf2 has been implicated in CMD34 and aging and longevity35,36 and regulates many genes involved in oxidative stress, inflammation, drug conjugation and detoxification, and mitochondrial biogenesis.37 Eicosanoids—central mediators of initiation and resolution of inflammation—also emerged from these studies as linked to stress. Several metabolites associated with CM stress in this study have been previously modified to ameliorate mechanisms of CVD: supplementation of taurine and arginine (higher levels associated with lower CM stress) may improve endothelial function, inflammation, oxidative stress, and atherogenesis.38-40 Some metabolites may be associated with dietary exposures,41 suggesting the potential for nutritional interventions.

**Limitations**

This study has some limitations. The results of this study should be viewed in the context of its design. The effect size of the metabolite-based CM stress score for CHD and mortality was smaller relative to other protein-based markers that are closer to disease (eg, high-sensitivity troponin42), which may limit direct clinical translation. We limited the metabolites included and used a priori–defined imputation, which may introduce biased regression estimates, although restriction of metabolites expressed in most participants mitigates this risk. Second, the subset of overlapping metabolites was limited between the BPRHS and the ARIC study, which may have led to submaximal model performance. Our results are based on 2 different observational studies (the BPRHS and the ARIC study) with disparate prevalent CMD and racial composition and residual confounding (eg, cancer and HIV infection in the BPRHS), and the use of a CM stress score (as opposed to its metabolic components) may limit discovery for each individual parameter of the score. Further studies in large composite cohorts should be performed to address imputation, unannotated metabolite significance, confounding, and different end points (eg, cancer or diabetes). Third, while these studies only accessed circulating metabolites (limiting the ability to infer a direct cellular role), there are many examples of circulating metabolite–based mechanistic discoveries that begin in clinical observation.43-45 Pathway analysis remains a strictly exploratory method, with continuous updating of annotated metabolite-gene databases that may improve mapping and candidate pathway identification for mechanistic study.

**Conclusions**

Metabolite signatures linked to CM stress specify known and novel pathways and are linked to CVD and all-cause mortality at a 30-year horizon. These findings provide evidence of the shared metabolic underpinnings of CMD and CVD, indicate novel loci for mechanistic investigation, and highlight the role of metabolic characterization in human studies in the targeting and prevention of CVD.

**ARTICLE INFORMATION**

Accepted for Publication: May 17, 2020.
Published Online: July 22, 2020.

**Author Affiliations:** Frankel Cardiovascular Center, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor (Murthy); Department of Epidemiology, Human Genetics and Environmental Sciences, University of Texas Health Science Center at Houston School of Public Health, Houston (Yu, Wang, Alkis, Bressler, Boerwinkle); Department of Biomedical and Nutritional Sciences, University of Massachusetts, Lowell, Lowell (Zhang, Tucker); Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, California (Pico); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston (Yerai, Shah); Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts (Bhupathiraju); Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts (Bhupathiraju); Department of Medicine, Baylor College of Medicine, Houston, Texas (Ballantyne); UMass Memorial Heart and Vascular Center, University of Massachusetts Medical School, Worcester (Freedman); Friedman School of Nutrition Science and Policy, School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts (Ordovas).

**Author Contributions:** Drs Yu and Shah had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Murthy and Yu contributed equally. Drs Murthy, Boerwinkle, Tucker, and Shah jointly supervised the work. Concept and design: Murthy, Ordovas, Tucker, Shah. Acquisition, analysis, or interpretation of data: Murthy, Yu, Wang, Zhang, Alkis, Pico, Yerai, Bhupathiraju, Bressler, Ballantyne, Freedman, Boerwinkle, Tucker, Shah. Drafting of the manuscript: Murthy, Yu, Wang, Zhang, Pico, Shah. Critical revision of the manuscript for important intellectual content: Murthy, Yu, Alkis, Pico, Yerai, Bhupathiraju, Bressler, Ballantyne, Freedman, Ordovas, Boerwinkle, Tucker, Shah.

**Statistical analysis:** Murthy, Yu, Wang, Zhang, Alkis, Yerai, Bhupathiraju, Shah.

** Obtained funding:** Bhupathiraju, Ordovas, Boerwinkle, Tucker.

**Administrative, technical, or material support:** Yu, Freedman.

**Supervision:** Shah.

**Conflict of Interest Disclosures:** Dr Murthy reported receiving grants from Singulex; having minor stock holdings in General Electric; other support from Cardinal Health; personal fees and stock options from Ionetix; personal fees from Covidien and Jubilant Draximge; and grants and personal fees from Siemens outside the submitted work. Dr Bressler reported receiving grants from the National Institutes of Health/National Heart, Lung, and Blood Institute during the conduct of the study. Dr Boerwinkle reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Tucker reported receiving

© 2020 American Medical Association. All rights reserved.
grants from the National Institutes of Health during the conduct of the study. Dr Shah reported receiving consulting fees from Amgen, Myokardia, and Best Doctors, being a co-inventor on a patent for ex-RNA signatures of cardiac remodeling, and having minor stock holdings in Gilead. No other disclosures were reported.

Funding/Support: Drs Murthy, Yu, Pico, Bhupathiraju, Bressler, Ballantyne, Freedman, Boerwinkle, Tucker, and Shah received grants from the National Institutes of Health. Dr Yu is also supported by grant 175DG3660228 from the American Heart Association. The Boston Puerto Rican Health study has been funded by grant P50-HL105185 from the National Heart, Lung, and Blood Institute and grants PO1-AG2394 and ROI-AG055948 from the National Institute on Aging. The Atherosclerosis Risk in Communities study has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under contract HHSN268201000011, HHSN268201000021, HHSN268201000031, and HHSN268201000041. The metabolomics measurements were supported by grant HGO04402 from the National Genome Research Institute and by grant KO1 DK107804 from the National Institutes of Health (Dr Bhupathiraju; for the Boston Puerto Rican Health Study).

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES


© 2020 American Medical Association. All rights reserved.


